Colrain Capital’s Biogen BIIB Stock Holding History

Colrain Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,500	Closed	-$651K	–	86
2016 Q1	$651K	Buy	+2,500	New	+$660K	0.11%	65

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Colrain Capital's BIIB Position: Q2 2016 in Review

Colrain Capital sold out of Biogen (BIIB) in Q2 2016, closing a stake of 2,500 shares — an estimated $651K sold.

Colrain Capital first reported a position in BIIB in Q1 2016 and held it in 1 quarter. The position peaked at $651K in Q1 2016. 965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

Colrain Capital reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
Colrain Capital sold 2,500 Biogen shares in Q2 2016, an estimated $651K.
Colrain Capital first reported a position in Biogen in Q1 2016 and held it in 1 quarter.
Colrain Capital's Biogen position peaked at $651K in Q1 2016.
965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Colrain Capital's 13F filing for Q2 2016, filed 5 Aug 2016.